Beacon of hope for IgA nephropathy community as full approval granted to Tarpeyo 02-Jan-2024 By Liza Laws The US Food and Drink Administration (FDA) has approved Calliditas Therapeutics' Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with IgAN.